HCW Biologics Faces Delisting Notice
Ticker: HCWB · Form: 8-K · Filed: Oct 16, 2025 · CIK: 1828673
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
TL;DR
HCW Biologics got a delisting warning, stock might be in trouble.
AI Summary
HCW Biologics Inc. filed an 8-K on October 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, effective October 13, 2025. The company is incorporated in Delaware and its principal executive offices are located in Miramar, Florida.
Why It Matters
This filing indicates potential issues with HCW Biologics Inc.'s continued listing on an exchange, which could significantly impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and overall financial health.
Key Numbers
- 001-40591 — Commission File Number (Identifies the company's SEC filing history.)
- 82-5024477 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- HCW Biologics Inc. (company) — Registrant
- October 13, 2025 (date) — Date of earliest event reported
- October 16, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Miramar, Florida (location) — Address of Principal Executive Offices
- 954 842-2024 (phone_number) — Registrant's Telephone Number
FAQ
What specific listing rule or standard has HCW Biologics Inc. failed to satisfy?
The filing does not specify the exact rule or standard that HCW Biologics Inc. has failed to satisfy, only that a notice has been received.
What is the effective date of the notice of delisting or failure to satisfy a continued listing rule?
The earliest event reported, which is the date of the notice, is October 13, 2025.
What actions, if any, does HCW Biologics Inc. plan to take in response to this notice?
The provided text does not detail any specific actions HCW Biologics Inc. plans to take in response to the notice.
Where are HCW Biologics Inc.'s principal executive offices located?
HCW Biologics Inc.'s principal executive offices are located at 2929 N. Commerce Parkway, Miramar, Florida 33025.
What is the Commission File Number for HCW Biologics Inc.?
The Commission File Number for HCW Biologics Inc. is 001-40591.
Filing Stats: 690 words · 3 min read · ~2 pages · Grade level 13 · Accepted 2025-10-16 09:00:25
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share HCWB The Nasdaq Stock Mar
Filing Documents
- hcwb-20251013.htm (8-K) — 42KB
- 0001193125-25-240890.txt ( ) — 145KB
- hcwb-20251013.xsd (EX-101.SCH) — 24KB
- hcwb-20251013_htm.xml (XML) — 5KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on August 19, 2025, HCW Biologics Inc. (the "Company") received written notice from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") that as of June 30, 2025, the Company was non-compliant with Listing Rule 5550(b)(1), the "Equity Rule" for continued listing on The Nasdaq Capital Market (the "Exchange"). The Company made a timely request for a hearing before the Nasdaq Hearings Panel (the "Panel") and was granted a hearing, which was held on September 25, 2025. On October 13, 2025, the Panel granted the Company an extension in which to regain compliance with all continued listing rules of the Exchange. The Panel's determination follows the Company's hearing on September 25, 2025, at which the Company presented, and the Panel considered, the Company's plan to regain compliance with the Equity Rule. The Panel granted the Company's request for continued listing on the Exchange, subject to, among other things, the Company demonstrating compliance with the Equity Rule by December 31, 2025, and with all other Exchange continued listing rules by February 16, 2026. The Company was advised that February 16, 2026, represents the full extent of the Panel's discretion to grant continued listing while the Company is non-compliant with the Nasdaq Listing Rules. The Panel also required that the Company provide prompt notification of any significant events that occur during the exception period that may affect the Company's compliance with Nasdaq requirements. In addition, the Company must timely file Form 10-Q for the third quarter, and provide notice of the status of certain elements of the Company's compliance plan. Any compliance documentation submitted by the Company will be subject to review by the Panel, which may, in its discretion, request additional information before determining that the Comp
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HCW BIOLOGICS INC. Date: October 16, 2025 By: /s/ Hing C. Wong Hing C. Wong, Founder and Chief Executive Officer